Search Patents
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20110160183
    Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: March 11, 2011
    Publication date: June 30, 2011
    Applicant: Merck & Co., Inc.
    Inventors: Michael J. Kelly, III, Mark E. Layton, Philip E. Sanderson
  • Anti-phospho-Akt antibodies
    Patent number: 9739781
    Abstract: The Present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: August 22, 2017
    Assignee: NMDX, LLC
    Inventor: Patrick J. Muraca
  • Akt Nucleic Acids, Polypeptides, and Uses Thereof
    Publication number: 20120034188
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: August 1, 2011
    Publication date: February 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20130102605
    Abstract: The instant invention provides for substituted thiazoles that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 25, 2013
    Inventors: Peng Liang, Morihiro Mitsuya, Yoshio Ogino, Changhe Qi, Hidekazu Takahashi, Paul Tempest, Jiabing Wang, Yuguang Wang, Zhenzhen Wang, Shaohua Zhang, Nanyan Zhou, Jiuxiang Zhu
  • ANTI-PHOSPHO-AKT ANTIBODIES
    Publication number: 20100092473
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Application
    Filed: November 13, 2009
    Publication date: April 15, 2010
    Applicant: Nuclea Biotechnologies LLC
    Inventor: Patrick J. Muraca
  • Specific Akt3 Inhibitor and Uses Thereof
    Publication number: 20190269672
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Application
    Filed: May 20, 2019
    Publication date: September 5, 2019
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva
  • EEF2K as modifiers of the PTEN/AKT pathway and methods of use
    Patent number: 8679763
    Abstract: Human EEF2K genes are identified as modulators of the PTEN/AKT pathway and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT comprising screening for agents that modulate the activity of EEF2K are provided.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: March 25, 2014
    Assignee: Exelixis, Inc.
    Inventors: Arthur Brace, Robert A. Blake, Lori S. Friedman, Lynn Margaret Bjerke, Kevin M. Ward, Susana Nieto-Bergman
  • AKT nucleic acids, polypeptides, and uses thereof
    Patent number: 6881555
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: April 19, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications
    Publication number: 20170202829
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Application
    Filed: January 17, 2017
    Publication date: July 20, 2017
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, lryna Lebedyeva
  • AKT1 MODULATORS
    Publication number: 20240174667
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 30, 2024
    Inventors: Michael David BARTBERGER, Elena V. DNEPROVSKAIA, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY
    Publication number: 20120142624
    Abstract: Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.
    Type: Application
    Filed: May 21, 2010
    Publication date: June 7, 2012
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Sherry X. Yang, Sandra M. Swain
  • AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
    Patent number: 8546091
    Abstract: Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: October 1, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sherry X. Yang, Sandra M. Swain
  • Specific Akt3 inhibitor and uses thereof
    Patent number: 11013735
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 25, 2021
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Specific Akt3 inhibitor and uses thereof
    Patent number: 10292978
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 21, 2019
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva
  • Inhibitors of AKT activity
    Patent number: 8691825
    Abstract: The instant invention provides for substituted fused pyrimidine compounds of Formula A that inhibit Akt activity: In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Qi Chen, Mingxiang Cui, Bin Hu, Shuangxi Hu, Zhifa Pu, Philip E. Sanderson, Richard Soll, Xue Tang, Jiabing Wang, Yongjin Yan, Jinfeng Yao, Hongjie Zhang
  • Substituted naphthyridine compounds as inhibitors of Akt activity
    Patent number: 8288407
    Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: October 16, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael J. Kelly, III, Mark E. Layton, Philip E. Sanderson
  • Anti-phospho-Akt antibodies
    Patent number: 9029512
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 12, 2015
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • AKT SENSITIZATION OF CANCER CELLS
    Publication number: 20080131526
    Abstract: Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type p53. Breast, ovarian, lung cancer and leukemia cells lines were treated with combinations of Akt activation inhibitor Triciribine (TCN) or Triciribine phosphate (TCNP) and chemotherapeutic drugs to determine the efficiency of combination therapy. Additionally, cells were introduced into xenograft models to determine in vivo effects of combination treatment. Combining TCN or TCNP with other anticancer drugs overcame cytotoxic or treatment resistance. Thus, TCN and TCNP are shown to broaden the spectrum of human tumors that can be effectively treated.
    Type: Application
    Filed: October 4, 2007
    Publication date: June 5, 2008
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Said M. Sebti, Jin Q. Cheng
  • Inhibitors Of AKT Activity
    Publication number: 20120077810
    Abstract: The instant invention provides for substituted fused pyrimidine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: March 29, 2010
    Publication date: March 29, 2012
    Inventors: Qi Chen, Mingxiang Cui, Bin Hu, Shuangxi Hu, Zhifa Pu, Philip E. Sanderson, Richard Soll, Xue Tang, Jiabing Wang, Yongjin Yan, Jinfeng Yao, Hongjie Zhang
  • Inhibitors of Akt activity
    Patent number: 7576209
    Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: August 18, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Michael J. Kelly, III, Mark E. Layton, Philip E. Sanderson
Narrow Results

Filter by US Classification